Sponsors are largely being left to their own devices when determining information is "consistent with" FDA-approved drug labeling, at least for now, as the agency plans a case-by-case approach.
The agency's inability to provide more general clarity may force sponsors to watch for enforcement action from the US agency or wait for individual advisory comments to better understand its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?